Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Cloudbreak Pharma, Inc. ( (HK:2592) ) is now available.
Cloudbreak Pharma Inc. has announced a positive profit alert for the first half of 2025, expecting to record a consolidated net profit before income tax of no less than US$4.5 million. This marks a significant turnaround from the previous year’s net loss of approximately US$52.1 million. The improvement is largely attributed to positive fair value changes of convertible redeemable preferred shares, which were converted to ordinary shares following the company’s initial public offering. Despite this, the company anticipates a consolidated net loss of no less than US$32.8 million when excluding these fair value changes, indicating an increase in losses from the previous period.
More about Cloudbreak Pharma, Inc.
Cloudbreak Pharma Inc. is a pharmaceutical company incorporated in the Cayman Islands with a focus on developing and commercializing innovative healthcare solutions. It operates in the pharmaceutical industry and is listed on the Stock Exchange of Hong Kong.
Average Trading Volume: 2,321,311
For detailed information about 2592 stock, go to TipRanks’ Stock Analysis page.